Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Gross Margin (2024 - 2025)

Historic Gross Margin for Celldex Therapeutics (CLDX) over the last 6 years, with Q2 2025 value amounting to 111.51%.

  • Celldex Therapeutics' Gross Margin fell 1468600.0% to 111.51% in Q2 2025 from the same period last year, while for Sep 2025 it was 47.19%, marking a year-over-year decrease of 719300.0%. This contributed to the annual value of 43.23% for FY2013, which is 394100.0% up from last year.
  • Celldex Therapeutics' Gross Margin amounted to 111.51% in Q2 2025, which was down 1468600.0% from 211.94% recorded in Q1 2025.
  • Celldex Therapeutics' 5-year Gross Margin high stood at 66.34% for Q3 2024, and its period low was 738.46% during Q1 2024.